These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2849127)

  • 41. Protection of mice against fission neutron irradiation by WR-2721 or WR-151327.
    Steel LK; Jacobs AJ; Giambarresi LI; Jackson WE
    Radiat Res; 1987 Mar; 109(3):469-78. PubMed ID: 3031721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration.
    Fatome M; Courteille F; Laval JD; Roman V
    Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Jul; 52(1):21-9. PubMed ID: 3036725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiosensitisation and radioprotection by BSO and WR-2721: the role of oxygenation.
    Durand RE; Olive PL
    Br J Cancer; 1989 Oct; 60(4):517-22. PubMed ID: 2553091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An improved HPLC assay for S-2-(3-aminopropylamino)ethyl phosphorothioate (WR-2721) in plasma.
    Swynnerton NF; McGovern EP; Niño JA; Mangold DJ
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1521-4. PubMed ID: 6090354
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Response of mouse tissues to neutron and gamma radiation: protection by WR-3689 and WR-77913.
    Rasey JS; Magee S; Nelson N; Chin L; Krohn KA
    Radiother Oncol; 1990 Feb; 17(2):167-73. PubMed ID: 2157242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. WR-2721: a chemotherapy and radiation-protective agent.
    Schein PS
    Cancer Invest; 1990; 8(2):265-6. PubMed ID: 2169331
    [No Abstract]   [Full Text] [Related]  

  • 47. Is the outlook grey for WR-2721 as a clinical radioprotector?
    Denekamp J; Stewart FA; Rojas A
    Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1247-9. PubMed ID: 6307942
    [No Abstract]   [Full Text] [Related]  

  • 48. Radiation-induced DNA single-strand breaks in the intestinal mucosal cells of mice treated with the radioprotectors WR-2721 or 16-16 dimethyl prostaglandin E2.
    Hanson WR; Grdina DJ
    Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Jul; 52(1):67-76. PubMed ID: 3036726
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography.
    Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML
    Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The distribution and metabolism of the radiation protective agent aminopentylaminoethylphosphorothioate in mice.
    Kollmann G; Martin D; Shapiro B
    Radiat Res; 1971 Dec; 48(3):542-50. PubMed ID: 5137463
    [No Abstract]   [Full Text] [Related]  

  • 51. Measurement of WR-2721, WR-1065, and WR-33278 in plasma.
    Fahey RC; Newton GL
    Int J Radiat Oncol Biol Phys; 1985 Jun; 11(6):1193-7. PubMed ID: 2987166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can WR-2721 be improved upon?
    Brown DQ; Graham WJ; MacKenzie LJ; Pittock JW; Shaw LM
    Pharmacol Ther; 1988; 39(1-3):157-68. PubMed ID: 2849121
    [No Abstract]   [Full Text] [Related]  

  • 53. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution.
    Rasey JS; Nelson NJ; Mahler P; Anderson K; Krohn KA; Menard T
    Radiat Res; 1984 Mar; 97(3):598-607. PubMed ID: 6328565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protection by WR-3689 against gamma-ray-induced intestinal damage: comparative effect on clonogenic cell survival, mouse survival, and DNA damage.
    Murray D; Altschuler EM; Hunter N; Milas L
    Radiat Res; 1989 Nov; 120(2):339-51. PubMed ID: 2559423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
    Bonner HS; Shaw LM
    J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radioprotective effect of WR-2721 on haematopoiesis in mice. I. Quantitative changes in haematopoiesis.
    Brezáni P; Macková N
    Radiobiol Radiother (Berl); 1988; 29(5):587-93. PubMed ID: 2852382
    [No Abstract]   [Full Text] [Related]  

  • 57. Radioprotective effect of WR-2721 in rabbits: a comparison with cystamine.
    Kuna P; Petýrek P; Jensovský V; Melek J
    Radiobiol Radiother (Berl); 1981; 22(5):644-52. PubMed ID: 6280232
    [No Abstract]   [Full Text] [Related]  

  • 58. [Responses to radiation of Ehrlich ascites tumor cells in the presence of YM-08310 (=WR-2721) and/or Ro-07-0582 (in vivo, in vitro assay)].
    Ebe K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1987 Feb; 47(2):307-17. PubMed ID: 3039456
    [No Abstract]   [Full Text] [Related]  

  • 59. Specific protection of different normal tissues.
    Rasey JS; Spence AM; Badger CC; Krohn KA; Vera DM; Livesey JC
    Pharmacol Ther; 1988; 39(1-3):33-43. PubMed ID: 2849132
    [No Abstract]   [Full Text] [Related]  

  • 60. Transdermal absorption of radioprotectors using permeation-enhancing vehicles.
    Sodicoff M; Lamperti A; Ziskin MC
    Radiat Res; 1990 Feb; 121(2):212-9. PubMed ID: 2154835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.